This post may contain affiliate links. Please read my disclosure statement for more info.Through the years, I have interviewed hundreds of millionaires with the goal of learning from their experiences and knowledge.I’ve published these as Millionaire Interviews, featuring my specific questions and their responses.After a few hundred interviews, I realized that there was phenomenal wisdom in several of the questions I asked, especially when the responses from different interviewees are read one after another ...

Core Viewpoint - The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as an ideal investment for income-focused investors, offering a combination of high yield and potential capital gains through a diversified portfolio of stocks [2][4]. Group 1: ETF Overview - The Schwab U.S. Dividend Equity ETF has been established for 14 years and is managed by Charles Schwab, boasting over $71 billion in net assets, making it one of the largest high-yield ETFs [4]. - The ETF has a low expense ratio of 0.06%, ensuring that investors are not overpaying for its benefits [5]. - It pays quarterly dividends with a 30-day SEC yield of 3.8%, which is close to the 10-year Treasury rate of 4.2%, providing a competitive passive income option [6]. Group 2: Investment Strategy - The ETF targets large-cap, high-yield stocks, with approximately 90% of its investments in companies with market capitalizations exceeding $15 billion, appealing to investors seeking diversification [8]. - Over half of the ETF's investments are concentrated in three sectors: energy, consumer staples, and healthcare, which are known for prioritizing dividend growth [9]. Group 3: Sector and Holdings - Key energy holdings include major companies like Chevron, ConocoPhillips, and EOG Resources, which help manage risk across the oil and gas value chain [10]. - The top healthcare holdings, such as Merck and Amgen, offer high yields and favorable valuations, while leading consumer staples like PepsiCo and Coca-Cola have consistently raised dividends for over 50 years, earning the title of Dividend Kings [11]. Group 4: Performance and Value - Since its inception in October 2011, the Schwab U.S. Dividend Equity ETF has more than tripled in value, demonstrating its potential for capital gains alongside dividend income [13]. - The ETF is positioned as a foundational holding for value-focused portfolios or as a means to balance portfolios that have become overly concentrated in growth stocks [12].

Company Overview - MiniMed, a diabetes management firm, is planning an IPO after separating from Medtronic [1] Financial Performance - The company is experiencing growing revenue [1] - The company is experiencing a shrinking net loss [1]

Business Practices Review - UnitedHealth Group commissioned outside reviews of its business practices [1] - The reports describe UnitedHealth's policies as "robust" [1] - The reports also point to ongoing problems in areas that have faced scrutiny [1]

IPO Plans - Sunway Healthcare is expected to begin gauging investor interest for an IPO as early as January [1] - The potential IPO aims to raise approximately $700 million (7 亿美金) [1] Company Information - Sunway Healthcare is based in Malaysia [1]

Core Insights - Vanguard 500 Index Fund ETF Shares (NASDAQ:VOO) leads the ETF market with $1.5 trillion in assets and a low expense ratio of 0.03%, but ProShares S&P 500 Dividend Aristocrats ETF (NYSEARCA:NOBL) offers superior cash flow with a yield of 2.1% compared to VOO's 1.09% [2][4] Group 1: NOBL's Income Generation - NOBL generates income solely from dividends of 68 blue-chip Dividend Aristocrats, which have a history of increasing dividends for over 25 years [3][4] - The ETF employs an equal-weighting methodology, with sector allocations of 22.5% in Industrials and 20.9% in Consumer Staples, minimizing concentration risk while maximizing exposure to reliable dividend payers [3][4] Group 2: Dividend Safety Analysis - Albemarle Corporation, with a 2.06% weighting, faces risks due to negative earnings of -$1.59 per share but maintains a $1.62 annual dividend [5] - Caterpillar, holding a 1.68% weighting, shows strong performance with a 46.3% return on equity and a 14.3% profit margin, supported by a $5.84 annual dividend and $19.49 in earnings [5] - Johnson & Johnson, with a 1.51% weighting, offers a 2.37% yield and has a 74% payout ratio, backed by a 27.3% profit margin and over 60 years of consecutive dividend increases [5] - Walmart and Procter & Gamble, with weightings of 1.56% and 1.33% respectively, maintain conservative payout ratios of 32% and 60%, generating significant free cash flow to support dividend growth [5]

IPO Details - Medline had the largest IPO in over four years, offering $626 billion [1] - The IPO was unexpected, as Medline is not a widely recognized name [1] Business Model & Strategy - Medline's revenue is evenly split between its own brand medical surgical products and supply chain solutions [2] - Earnings are primarily derived from product sales [2] - The supply chain business provides insights into hospital needs and facilitates product distribution [2] - Medline aims to be the "Costco of healthcare" [3] - It employs a membership model through its supply chain business to offer healthcare providers the best prices [3] - Medline brand products are positioned similarly to Costco's Kirkland signature brand [3] Revenue Growth - Medline experienced solid revenue growth in recent years: 83% in 2023, 98% in 2024, and 103% through the first 9 months of 2025 [4] - Revenue growth appears to be accelerating [4]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

SRx Health (SRXH) shares soared a remarkable 85% on Dec. 16 after the Florida-based company announced a pivot into digital asset treasury management. As part of this pivot, the health and wellness firm has agreed to merge with EMJ Crypto Technologies (EMJX) in an all-stock deal valued at about $55 million. More News from Barchart Eric Jackson, a renowned hedge fund manager, will lead the joint company once the transaction closes in the first quarter of 2026. At one point after the EMJ announcement, SR ...

Joining us right now first on CNBC is Medline CEO Jim Bole. Good morning to you. >> Good morning.>> Congratulations. This been this has been a quite a road for you to get to to this point. Uh why go public now.What's the what's what's the thinking in terms of where you came from and where you are right now. >> And as you know, we've been a private company for 58 years. Um with 58 years of consecutive growth, uh we just feel like this is the right time for us to kind of expand our voice.Historically, we've d ...